Researchers presented new findings Saturday at a breast-cancer symposium here suggesting that the risks associated with anthracyclines, a class of chemotherapy drugs widely used to treat the disease, outweighed their benefits in some patients.The findings renewed a debate over whether anthracyclines, which have been around since the 1960s, should remain the standard of care in treating breast cancer, or whether newer drugs should be used more frequently instead.
More...
Advocate Health, the third largest non-profit health system in the country, has announced it will cancel...
or the first time in decades, public health data shows a sudden and hopeful drop in...
